Signatera MRD Assay Predicts Chemotherapy Survival Benefit in Metastatic Colorectal Cancer
NTRA•Signatera’s personalized circulating tumor DNA minimal residual disease assay predicted which patients with resected metastatic colorectal cancer would achieve an overall survival benefit from adjuvant chemotherapy. The test stratified MRD-positive patients for targeted post-surgical treatment, demonstrating its potential to guide adjuvant therapy decisions in this high-risk population.
1. Signatera MRD Assay Overview
Signatera is a personalized circulating tumor DNA assay designed to detect minimal residual disease in patients after tumor resection. It uses patient-specific somatic mutations to monitor MRD status and inform treatment strategies based on ctDNA dynamics.
2. Study Findings
In patients with resected metastatic colorectal cancer, MRD-positive individuals identified by the test demonstrated a clear overall survival advantage when treated with adjuvant chemotherapy. The analysis showed that MRD status correlated with differential outcomes, highlighting the assay’s prognostic value.
3. Implications for Clinical Practice
These findings support integration of Signatera into post-surgical decision-making workflows, enabling clinicians to tailor adjuvant therapy to patients most likely to benefit. The assay’s stratification capability may improve survival rates and optimize resource allocation for high-risk colorectal cancer populations.
